Roche insists Perjeta combo shows OS advantage in metastatic breast cancer
This article was originally published in Scrip
Roche/Genentech has said it has encouraging data on overall survival in HER2-positive metastatic breast cancer for the combination of its two HER2 targeted antibodies, Perjeta (pertuzumab) and Herceptin. The antibody combination apparently gave better overall survival in the CLEOPATRA study than Herceptin, when both regimes were used with a background of docetaxel chemotherapy. However, the magnitude of the overall survival advantage is unclear and may not be known until the data appear are presented at a medical meeting.